Prime Medicine, Inc./$PRME
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Ticker
$PRME
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
214
ISIN
US74168J1016
Website
PRME Metrics
BasicAdvanced
$407M
-
-$1.61
1.90
-
Price and volume
Market cap
$407M
Beta
1.9
52-week high
$3.50
52-week low
$1.11
Average daily volume
3M
Financial strength
Current ratio
4.776
Quick ratio
4.208
Long term debt to equity
106.892
Total debt to equity
113.306
Profitability
EBITDA (TTM)
-200.005
Gross margin (TTM)
-3,941.08%
Net profit margin (TTM)
-5,252.50%
Operating margin (TTM)
-5,369.68%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-40.36%
Return on equity (TTM)
-115.21%
Valuation
Price to revenue (TTM)
101.247
Price to book
3.71
Price to tangible book (TTM)
3.71
Price to free cash flow (TTM)
-3.495
Free cash flow yield (TTM)
-28.61%
Free cash flow per share (TTM)
-88.98%
Growth
Revenue change (TTM)
550.76%
Earnings per share change (TTM)
-25.19%
3-year earnings per share growth (CAGR)
-41.22%
Bulls say / Bears say
Prime Medicine's strategic restructuring focuses on large genetic liver diseases and cystic fibrosis, potentially expanding its market reach and revenue streams. (globenewswire.com)
The company reported a significant increase in cash, cash equivalents, and investments to $144.3 million as of March 31, 2025, enhancing its financial stability. (investors.primemedicine.com)
Positive initial data from the Phase 1/2 clinical trial of PM359 in Chronic Granulomatous Disease (CGD) provides clinical proof-of-concept for Prime Editing technology. (globenewswire.com)
Prime Medicine reported a net loss of $51.9 million for Q1 2025, indicating ongoing financial challenges. (investors.primemedicine.com)
The company's operating expenses increased to $53.8 million in Q1 2025, up from $48.9 million in the same period the previous year, reflecting rising costs. (investors.primemedicine.com)
Despite increased cash reserves, the company's cash, cash equivalents, and investments decreased from $190.4 million at the end of 2024 to $144.3 million by March 31, 2025, suggesting a high burn rate. (investors.primemedicine.com)
Data summarised monthly by Lightyear AI. Last updated on 26 Jun 2025.
PRME News
AllArticlesVideos
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
GlobeNewsWire·2 months ago
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
GlobeNewsWire·2 months ago
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prime Medicine, Inc. stock?
Prime Medicine, Inc. (PRME) has a market cap of $407M as of July 05, 2025.
What is the P/E ratio for Prime Medicine, Inc. stock?
The price to earnings (P/E) ratio for Prime Medicine, Inc. (PRME) stock is 0 as of July 05, 2025.
Does Prime Medicine, Inc. stock pay dividends?
No, Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Prime Medicine, Inc. dividend payment date?
Prime Medicine, Inc. (PRME) stock does not pay dividends to its shareholders.
What is the beta indicator for Prime Medicine, Inc.?
Prime Medicine, Inc. (PRME) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.